Navigation Links
Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002

PLYMOUTH, Mich., Jan. 6, 2011 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate. ETC-1002 is a novel small molecule compound that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism. The compound acts to inhibit fatty acid and cholesterol synthesis and enhance fatty acid oxidation. ETC-1002 has the potential to regulate LDL-C, HDL-C, triglycerides, glucose/insulin and other cardio-metabolic risk factors.

The 12-week, multi-site, randomized, double-blind, placebo controlled study will enroll 176 patients with hypercholesterolemia, with or without high triglycerides, to assess the role of ETC-1002 in lipid regulation (LDL-C and triglycerides). This Phase 2 trial builds on positive data from the Phase 1 program in which ETC-1002 demonstrated a statistically significant lowering of LDL-C in mildly dyslipidemic subjects and a favorable safety profile in both single and multiple-dose studies in more than 70 patients. A second Phase 2 clinical study is planned in 2011 to validate other attributes observed in preclinical studies with ETC-1002 which further support its pharmacological effects as a metabolic regulator.

"Cardio-metabolic diseases remain the leading cause of morbidity and mortality among men and women in industrialized countries worldwide," said Roger Newton, PhD, President and CEO of Esperion. "Our preclinical research has shown ETC-1002 regulates lipids, atherosclerosis, inflammation and glucose/insulin. These data, along with the accumulating clinical evidence, suggest that ETC-1002 may be an effective therapy to regulate metabolic imbalances in lipid and carbohydrate metabolism and could play a significant role in the treatment of patients with symptoms characterized by metabolic syndrome. The efforts to advance ETC-1002 complement Esperion's other research and development program, focused on optimizing an HDL therapy in a strategic partnership with the Cleveland Clinic."

About Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company intends to commercialize innovative, first-in-class therapies focused on promoting cardio-metabolic health. For more information please visit ContactEsperion Therapeutics, Inc.734-862-4840

SOURCE Esperion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):